MENU
+Compare
GNOM
ETF ticker: NASDAQ
AS OF
Mar 10 closing price
Price
$8.77
Change
-$0.37 (-4.05%)
Net Assets
59.2M

GNOM stock forecast, quote, news & analysis

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index")... Show more

Category: #Health
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for GNOM with price predictions
Mar 10, 2025

Momentum Indicator for GNOM turns negative, indicating new downward trend

GNOM saw its Momentum Indicator move below the 0 level on February 20, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In of the 92 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on February 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

GNOM moved below its 50-day moving average on February 21, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GNOM entered a downward trend on March 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNOM's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

GNOM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 12.01B. The market cap for tickers in the group ranges from 38.96M to 125.39B. VRTX holds the highest valuation in this group at 125.39B. The lowest valued company is BLUE at 38.96M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -1%. For the same ETF, the average monthly price growth was -11%, and the average quarterly price growth was -20%. MRNA experienced the highest price growth at 19%, while CDNA experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was 28%. For the same stocks of the ETF, the average monthly volume growth was 50% and the average quarterly volume growth was 113%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 68
Price Growth Rating: 84
SMR Rating: 89
Profit Risk Rating: 87
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com